Laekna Advances Obesity Candidate LAE102 With Positive Phase I Data

Laekna, Inc. ( (HK:2105) ) just unveiled an update.

Laekna reported significant progress in 2025 across its R&D pipeline, highlighting advances in its obesity drug candidate LAE102, a monoclonal antibody against ActRIIA designed to promote muscle regeneration while reducing fat mass. The company’s operational focus remains on early-stage clinical validation of this asset, reinforcing its positioning in the competitive obesity and metabolic disorders market.

The company announced positive Phase I single ascending dose results for LAE102 in healthy volunteers, showing good tolerability, a favorable safety profile, and robust PK/PD correlation supporting further development. It also initiated and progressed a Phase I multiple ascending dose study in overweight and obese subjects, with preliminary data indicating increases in lean body mass and reductions in fat mass without serious adverse events, strengthening the clinical rationale for continued investment in LAE102 and potentially enhancing Laekna’s long-term growth prospects.

The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.

More about Laekna, Inc.

Laekna, Inc. is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong, focused on discovering and developing innovative drug candidates. Its pipeline includes internally discovered monoclonal antibodies targeting metabolic and muscle-related pathways, with a current market focus on treatments for obesity and muscle-preserving weight control.

Average Trading Volume: 2,183,340

Technical Sentiment Signal: Buy

Current Market Cap: HK$6.2B

See more data about 2105 stock on TipRanks’ Stock Analysis page.